The tolerability and safety profile of gabapentin

Reviews in Contemporary Pharmacotherapy

Volumn 7, Issue 5, 1996, Pages 249-257

  Walker, M C ^a   Patsalos, P N ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000883214     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994; 35: 795-801.
2. Anhut H, Ashman PJ, Feuerstein TJ et al. Long-term safety and efficacy of gabapentin as add-on therapy in patients with refractory partial seizures. J Epilepsy 1995a; 8: 44-50.
3. Anhut H, Greiner MJ, Murray GH. Double-blind, fixed-dose comparison study of gabapentin and carbamazepine monotherapy in patients with newly diagnosed partial epilepsy. Epilepsia 1995b; 36 (Suppl 4): 67.
4. Asconape J, Collins J, Gray B. Weight gain associated with the use of gabapentin. Epilepsia 1995a; 36 (Suppl 4): 72.
5. Asconape J, Diedrich A, DellaBadia J, Winston-Salem NC. Gabapentin associated myoclonus. Neurology 1995b; 45 (Suppl 4): A249-A250.
6. Bartoszyk GD, Meyerson N, Reimann W, Satzinger G, von Hodenberg A. Gabapentin. In: Meldrum BS, Porter RJ, eds. New Anticonvulsant Drugs. London: John Libbey, 1986: 147-163.
7. Bebin EM, Sofia RD, Dreifuss FE. Felbamate: toxicity. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. New York: Raven Press, 1995: 823-827.
8. Binnie CD, Debets RM, Engelsman M et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989; 4: 222-229.
9. Browne TR. Efficacy and safety of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine, 1993: 47-57.
10. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987; 50: 682-686.
11. Doherty KP, Gates JR, Penovich PE, Moriarty GL. Gabapentin in a medically refractory epilepsy population: seizure response and unusual side effects. Epilepsia 1995; 36 (Suppl 4): 71.
12. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995; 45: 594-595.
13. US Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994; 18: 67-73.
14. Walker MC, Sander JWAS. Overtreatment with antiepileptic drugs: how extensive is the problem? CNS Drugs 1994; 2: 335-340.
15. Walker MC, Patsalos PN. Clinical pharmacokinetics of new antiepileptic drugs. Pharmacol Ther 1995; 67: 351-384.
16. Wolf SM, Shinnar S, Kang H, Ballaban-Gil K, Moshe SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995; 36: 1203-1205.